BMP6 and type 2 diabetes mellitus: Interestingly, metformin, the first-line drug for T2D therapy, was recently shown to modulate iron metabolism by inhibiting bone morphogenetic protein 6 (BMP6)-induced hepcidin expression independently from protein kinase AMP-activated catalytic (AMPK) activation (canonical metformin activity) [172,173].